section name header

Indications ⬇

REMS

Unlabeled Use:

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: HF, changes in BP, tachycardia.

Derm: flushing, pruritus, sweating, urticaria.

EENT: excessive lacrimation, visual disturbances.

GI: diarrhea, GI bleeding, anorexia, cramps, dysphagia, HEPATOTOXICITY, nausea, vomiting.

GU: crystalluria, dysuria, erectile dysfunction, frequency, incontinence, nocturia.

Hemat: anemia, aplastic anemia, eosinophilia, leukopenia, thrombocytopenia.

Local: irritation at IV site, phlebitis.

MS: myalgia.

Neuro: drowsiness, muscle weakness, confusion, dizziness, headache, insomnia, malaise, nervousness.

Resp: dyspnea, pleural effusion, respiratory depression.

Misc: ANAPHYLAXIS, chills, drooling, fever.

Interactions ⬆ ⬇

Drug-Drug:

Drug-Natural Products:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

see Calculator

Spasticity

Prevention of Malignant Hyperthermia

Treatment of Malignant Hyperthermia

Neuroleptic Malignant Syndrome (unlabeled)

US Brand Names ⬆ ⬇

Dantrium, Revonto, Ryanodex

Action ⬆ ⬇

Therapeutic Effects:

Classifications ⬆ ⬇

Therapeutic Classification: skeletal muscle relaxants (direct acting)

Pharmacokinetics ⬆ ⬇

Absorption: 35% absorbed after oral administration. IV administration results in complete bioavailability.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Almost entirely metabolized by the liver.

Half-life: 8.7–11.4 hr.

Time/Action Profile ⬆ ⬇

(effects on spasticity)

ROUTEONSETPEAKDURATION
PO1 wkunknown6–12 hr
IVrapidrapidunknown

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

DAN-troe-leen audio

Code ⬆

NDC Code*